ALT Valuation

Altimmune Inc

Add to Watchlist

Advanced Chart

4.030

-0.05(-1.225%)1D

Overview
Forecast
Valuation
Earnings

ALT Relative Valuation

ALT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ALT is overvalued; if below, it's undervalued.

Historical Valuation

Altimmune Inc (ALT) is now in the Fair zone, suggesting that its current forward PS ratio of 98044.02 is considered Fairly compared with the five-year average of -5.24. The fair price of Altimmune Inc (ALT) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：4.08

Fair

-2.92

Trailing

Forward

-1.55

EV/EBITDA

Altimmune Inc. (ALT) has a current EV/EBITDA of -1.55. The 5-year average EV/EBITDA is -3.04. The thresholds are as follows: Strongly Undervalued below -8.59, Undervalued between -8.59 and -5.81, Fairly Valued between -0.26 and -5.81, Overvalued between -0.26 and 2.52, and Strongly Overvalued above 2.52. The current Forward EV/EBITDA of -1.55 falls within the Historic Trend Line -Fairly Valued range.

-1.48

EV/EBIT

Altimmune Inc. (ALT) has a current EV/EBIT of -1.48. The 5-year average EV/EBIT is -2.97. The thresholds are as follows: Strongly Undervalued below -8.39, Undervalued between -8.39 and -5.68, Fairly Valued between -0.26 and -5.68, Overvalued between -0.26 and 2.46, and Strongly Overvalued above 2.46. The current Forward EV/EBIT of -1.48 falls within the Historic Trend Line -Fairly Valued range.

97328.37

Altimmune Inc. (ALT) has a current PS of 97328.37. The 5-year average PS is 18093.00. The thresholds are as follows: Strongly Undervalued below -72591.03, Undervalued between -72591.03 and -27249.01, Fairly Valued between 63435.02 and -27249.01, Overvalued between 63435.02 and 108777.04, and Strongly Overvalued above 108777.04. The current Forward PS of 97328.37 falls within the Overvalued range.

-3.64

P/OCF

Altimmune Inc. (ALT) has a current P/OCF of -3.64. The 5-year average P/OCF is -2.34. The thresholds are as follows: Strongly Undervalued below -43.26, Undervalued between -43.26 and -22.80, Fairly Valued between 18.13 and -22.80, Overvalued between 18.13 and 38.59, and Strongly Overvalued above 38.59. The current Forward P/OCF of -3.64 falls within the Historic Trend Line -Fairly Valued range.

-3.65

P/FCF

Altimmune Inc. (ALT) has a current P/FCF of -3.65. The 5-year average P/FCF is -5.85. The thresholds are as follows: Strongly Undervalued below -11.08, Undervalued between -11.08 and -8.47, Fairly Valued between -3.24 and -8.47, Overvalued between -3.24 and -0.63, and Strongly Overvalued above -0.63. The current Forward P/FCF of -3.65 falls within the Historic Trend Line -Fairly Valued range.

Altimmune Inc (ALT) has a current Price-to-Book (P/B) ratio of 2.23. Compared to its 3-year average P/B ratio of 2.76 , the current P/B ratio is approximately -18.99% higher. Relative to its 5-year average P/B ratio of 2.60, the current P/B ratio is about -14.17% higher. Altimmune Inc (ALT) has a Forward Free Cash Flow (FCF) yield of approximately -24.10%. Compared to its 3-year average FCF yield of -21.50%, the current FCF yield is approximately 12.09% lower. Relative to its 5-year average FCF yield of -19.28% , the current FCF yield is about 24.99% lower.

2.23

P/B

Median3y

2.76

Median5y

2.60

-24.28

FCF Yield

Median3y

-21.50

Median5y

-19.28

Competitors Valuation Multiple

The average P/S ratio for ALT's competitors is 16234.49, providing a benchmark for relative valuation. Altimmune Inc Corp (ALT) exhibits a P/S ratio of 97328.37, which is 499.52% above the industry average. Given its robust revenue growth of 0.00%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

ALT.O

Altimmune Inc

97328.37

Average P/S: 16234.49

0.00%

326.86M

ALLO.O

Allogene Therapeutics Inc

Inhibrx Biosciences Inc

Rocket Pharmaceuticals Inc

67.43

335.06M

Performance Decomposition

Market capitalization of ALT decreased by 36.64% over the past 1 year. The primary factor behind the change was an decrease in Revenue Growth from 5.00K to 5.00K.

The secondary factor is the P/E Change, contributed -16.89%to the performance.

Overall, the performance of ALT in the past 1 year is driven by Revenue Growth. Which is more sustainable.

0.00%

5.00K → 5.00K

Revenue Growth

-19.75%

-487.88K → -391.50K

Margin Expansion

-16.89%

-3.93 → -3.26

P/E Change

-36.64%